Liquidia Corporation LQDA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Program Expenses by Product | ||||||
| Generic Treprostinil | $164K-54.9% | $364K-13.5% | $421K-23.7% | $552K-17.4% | $668K-7.2% | |
| L606 | $22.23M+13.0% | $19.68M+20.1% | $16.38M+10.1% | $14.88M+8.3% | $13.74M+14.0% | |
| Yutrepia | $61.57M+11.1% | $55.44M-4.8% | $58.26M+14.8% | $50.75M+25.4% | $40.48M+8.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Liquidia Corporation break its business down?
- Liquidia Corporation (LQDA) reports program expenses by product across 3 parts — Generic Treprostinil, L606 and Yutrepia. Each is extracted from the segment footnotes and tracked over time.
- Where does Liquidia Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Liquidia Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
